Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.

The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which exceeded analyst expectations. Immunovant reported a quarterly loss of $0.61 per share, beating the consensus estimate of $0.71 by 13.72% and marking a 19.74% improvement over the loss of $0.76 per share from the same period last year. The company's net loss of $110.64 million also came in better than the anticipated $125.06 million.

Investors were further encouraged by Immunovant's robust financial position. As of December 31, 2025, the clinical-stage immunology company reported cash and cash equivalents of $994.5 million. This strong balance sheet was recently bolstered by a $550 million financing round, extending the company's cash runway to support the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track, with topline data expected in 2026 and 2027.